The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, multi-center, safety, feasibility, and preliminary efficacy study evaluating a single dose of UNO101 in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies.
 
Frederick M. Dirbas
Consulting or Advisory Role - Beyond Cancer
 
Amichay Meirovitz
Research Funding - Beyond Cancer
 
David Greenberg
Consulting or Advisory Role - Beyond Cancer
 
Edith Dekel
Employment - Beyond Cancer; Karyopharm Therapeutics
Stock and Other Ownership Interests - Beyond Air; Karyopharm Therapeutics
Travel, Accommodations, Expenses - Beyond Cancer; Karyopharm Therapeutics
 
Gavin S. Choy
Employment - Rain Oncology, Inc. (I)
Leadership - Elucida Scientific Advisory Board
Stock and Other Ownership Interests - Lilly (I); Rain Oncology (I)
Honoraria - AstraZeneca; Gilead Sciences; Novartis; Pfizer; Roche/Genentech; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Novartis; Pfizer; Roche/Genentech; Stemline Therapeutics
Research Funding - Beyond Cancer, Inc.
Expert Testimony - Genentech
 
Jedidiah Monson
Employment - Beyond Cancer
Leadership - Beyond Cancer
Stock and Other Ownership Interests - Beyond Cancer
Travel, Accommodations, Expenses - Beyond Cancer